TY  - JOUR
AU  - Christopoulos, Petros
AU  - Thomas, Michael
PY  - 2017
TI  - A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC
JF  - Journal of Thoracic Disease; Vol 9, No 3 (March 28, 2017): Journal of Thoracic Disease
Y2  - 2017
KW  - 
N2  - In the Lancet issue of last December Rittmeyer and colleagues reported the primary efficacy analysis of another landmark immunotherapy study (1): the randomized phase 3 OAK trial comparing atezolizumab (n=425), an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, with docetaxel (n=425) for patients with squamous or adenocarcinomatous non-small cell lung cancer (NSCLC) progressing after one or more platinum-based combination regimens.
UR  - https://jtd.amegroups.org/article/view/12412